The peptide distribution market has two very different populations operating side by side. There are compliant, well-documented distributors operating within appropriate regulatory frameworks. And there are operations selling peptides with little or no documentation, no quality testing, and no concern for the liability they are passing to the clinics that order from them.
The challenge for clinic operators is that the two populations look similar on the surface. Both have professional websites. Both use the right terminology. Both offer similar product catalogs. The difference is in the documentation, the sourcing, the quality testing, and the business model.
Here are seven questions that will quickly separate the legitimate distributors from the ones you should not be sourcing from.
Question 1: Can You Provide a Certificate of Analysis for Every Lot?
A Certificate of Analysis (COA) is a document from an independent, accredited laboratory confirming the identity, purity, and quality of a specific lot of peptide. A legitimate distributor will provide a COA for every lot, issued by a third-party lab, without you having to ask.
Red flag: COAs issued only by the manufacturer or supplier themselves — not by an independent testing lab. Red flag: COAs that are not lot-specific, meaning the same document is provided for multiple batches. Red flag: any hesitation to provide COA documentation.
What to look for: COA from an accredited independent laboratory (look for ISO 17025 accreditation), showing minimum 98% purity for pharmaceutical-grade peptides, sterility testing results, and endotoxin/LAL testing results.
Question 2: What Is Your Regulatory Framework?
Ask directly: under what regulatory framework are you distributing these peptides? The legitimate answer for research-grade peptide distributors is some variation of: 'We distribute research-grade peptides to licensed healthcare providers for use in physician-supervised clinical research protocols. Our products are not FDA-approved drug products and are not distributed under a compounding pharmacy license.'
This framework is legally distinct from compounding and has different requirements. The distinction matters because the April 2026 FDA action on BPC-157 and TB-500 affects 503A/503B compounding; it does not necessarily affect research-grade distribution under a different framework. A distributor who cannot articulate their regulatory framework clearly does not understand it — which is a significant problem.
Question 3: Are You Registered With the FDA?
FDA registration is required for facilities that manufacture, process, pack, or hold drugs intended for human consumption. Research-grade peptide distributors are not drug manufacturers, but their source manufacturers typically are registered facilities. Ask about the manufacturing chain: where are the peptides synthesized, and is that facility FDA-registered?
A compliant supply chain will have documented facility registrations at the manufacturing level. A distributor who is reselling from an unregistered Chinese API manufacturer with no documentation is a very different risk profile than one sourcing from a registered US or European synthesis facility.
Question 4: Do You Require NPI Verification Before Selling?
Any legitimate distributor of research-grade peptides for clinical use should be verifying that their customers are licensed healthcare providers. The standard verification is NPI number check against the NPI registry, combined with a signed attestation of intended use.
A distributor who will sell to anyone — no license verification, no NPI check, no business verification — is not operating as a clinical supplier. They are operating as a gray-market retail operation, and your association with them creates compliance risk regardless of their product quality.
Question 5: What Is Your Return and Recall Policy?
Quality issues happen even in well-managed supply chains. The question is not whether a supplier has ever had a quality issue — it's how they handle it. A compliant distributor will have documented procedures for lot holds, voluntary recalls, and customer notification. They will be able to tell you how they would notify you in the event of a recall and how quickly.
A distributor who has no answer to this question — or who has never thought about it — is not running a serious quality management operation.
Question 6: Can You Provide a Supply Agreement?
A formal supply agreement that covers quality specifications, documentation requirements, pricing terms, and liability allocation is standard practice for clinical-supply relationships. It is not standard in the gray market. If a distributor will not put terms in writing, that tells you something about how they view the relationship.
Your supply agreement should include: quality specifications by peptide category, documentation requirements (COA, certificate of conformance), notification procedures for quality events, liability and indemnification language, and minimum purity and sterility standards.
Question 7: What Is Your Storage and Cold Chain Protocol?
Peptide stability depends on storage conditions. Properly manufactured peptides stored incorrectly will degrade, and degraded peptides can be inactive or, in some cases, generate impurities. A legitimate distributor will be able to clearly explain their storage requirements (typically lyophilized peptides at -20°C or lower), their cold chain management during shipping, and the expected shelf life under proper storage conditions.
Red flag: distributors who ship peptides without ice packs or cold chain documentation. Red flag: vague or inconsistent answers about storage requirements. Red flag: unusually long stated shelf lives that don't align with the chemistry.
Why This Due Diligence Matters
The documentation and vetting practices described above are not just about product quality — they are about your clinic's regulatory and legal position. A well-documented sourcing relationship, with a compliant distributor, providing properly characterized research-grade peptides to licensed providers under physician-supervised protocols, is a defensible position.
An undocumented relationship with a gray-market supplier is not defensible. When regulatory inquiries happen — and in the current enforcement environment, they do happen — your documentation is your protection.
Golden Lotus Labs provides COA documentation, supply agreements, NPI verification, FDA-registered manufacturing chain documentation, and full regulatory characterization with every order. We distribute exclusively to licensed healthcare providers. Contact us to review our documentation package and begin a sourcing conversation.